SCHEMBL6209540

SCHEMBL6209540

NC(=O)c1cc(O)c(N)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 4/20 0.43
HSD17B10 Q99714 3/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 1/20 0.43
IKBKB O14920 1/20 0.42
SLC9A1 P19634 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 3/20 0.37
PKM P14618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PPM1B O75688 1/20 0.36
CHUK O15111 1/20 0.36
CYP3A4 P08684 4/20 0.36
ALOX15 P16050 2/20 0.36
PARP1 P09874 1/20 0.35
MAPK1 P28482 1/20 0.35
CA12 O43570 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9673157 0.88 KDM4E (0.44) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL11666352 0.86 MAPT (0.43) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL5847055 0.82 IKBKB (0.50) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL24417899 0.81 IDO1 (0.52) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL17774896 0.80 DGAT1 (0.41) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL23511720 0.76 ALDH1A1 (0.52) MAPTALDH1A1KDM4EHSD17B10HPGD
Water SCHEMBL28292285 0.74 ALDH1A1 (0.50) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL21477551 0.73 KDM4E (0.50) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL9993737 0.73 KDM4E (0.42) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL5847061 0.73 IDO1 (0.54) MAPTALDH1A1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0907642-B1 PHENYLAMINO-SUBSTITUTED TRICYCLIC DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES PFIZER (US) 2005-11-02 EP disclosed
US-6596726-B1 Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme WARNER LAMBERT COMPANY 2003-07-22 US disclosed
US-6335344-B1 Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases PFIZER INC. 2002-01-01 US disclosed
EP-0907642-A1 PHENYLAMINO-SUBSTITUTED TRICYCLIC DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES PFIZER INC. (US) 1999-04-14 EP disclosed
WO-1997049688-A1 PHENYLAMINO-SUBSTITUTED TRICYCLIC DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES PFIZER INC. (US) 1997-12-31 WO disclosed
US-5679683-A USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS WARNER-LAMBERT COMPANY (US) 1997-10-21 US disclosed
EP-0741711-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1996-11-13 EP disclosed
WO-1995019970-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1995-07-27 WO disclosed